Per Falholt
Executive Vice President, Research & Development @ Novozymes
Copenhagen, Denmark
Per Falholt is a pre-seed investor at Novozymes in Copenhagen focused on Biotechnology and Robotics. A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Per Falholt invests in
Stages Per Falholt invests in
Countries Per Falholt invests in
Round sizes
Round size
- Series A
- $5.9M–$20M
Investment Focus
Industry
- Biotechnology 3 (60%)
- Robotics 1 (20%)
- Biopharma 1 (20%)
- Wholesale 1 (20%)
- Health Care 1 (20%)
Stage
- Pre-Seed 2 (40%)
- Series A 2 (40%)
- Seed 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $5.9M / Series A / Jan 22, 2026 | |
Synamics Therapeutics
|
Synamics Therapeutics redefines drug discovery by staying ahead of cancer's evolution. Its groundbreaking platform, Dynaptive, harnesses the power of AI to model and predict drug resistance. By designing compounds that preemptively overcome resistance, treatments remain effective longer, even as tumors evolve. | Pre-Seed / Jul 10, 2024 | |
Reshape Biotech
|
Reshape Biotech builds lab robots that automate the everyday tasks of microbiologists, from filling plates to analyzing images. | $20M / Series A / Apr 09, 2024 | |
|
Reshape Biotech
|
Reshape Biotech builds lab robots that automate the everyday tasks of microbiologists, from filling plates to analyzing images. | $8.1M / Seed / Feb 09, 2023 | |
Visibuilt
|
Visibuilt is to pioneer sustainable road-building solutions by replacing standard asphalt with cutting-edge, environmentally friendly materials. | $1.1M / Pre-Seed |
Co-Investors
About Novozymes
Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditionalchemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.
Novozymes Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Per Falholt
Executive Vice President, Research & Development
|
|||
Alvilde Storm
International Commercial Graduate
|
|||
Benny Loft
Executive Vice President and CFO, Corporate Functions
|
|||
Glenn Nedwin
President
|
|||
Lars Green
EVP and CFO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Per Falholt invest in?
Per Falholt invests primarily in Biotechnology, Robotics and Biopharma startups, most often at Pre-Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Per Falholt's check size?
Per Falholt typically joins rounds of $5.9M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Per Falholt participates in.
When did Per Falholt last invest?
The most recent investment recorded for Per Falholt closed in Jan 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
